- Home
- NNOX vs RIGL Comparison
NNOX vs RIGL Comparison
Compare NNOX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNOX
- RIGL
- Stock Information
- Founded
- NNOX 2011
- RIGL 1996
- Country
- NNOX Israel
- RIGL United States
- Employees
- NNOX N/A
- RIGL N/A
- Industry
- NNOX Medical Electronics
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- NNOX Health Care
- RIGL Health Care
- Exchange
- NNOX Nasdaq
- RIGL Nasdaq
- Market Cap
- NNOX 248.7M
- RIGL 335.5M
- IPO Year
- NNOX 2020
- RIGL 2000
- Fundamental
- Price
- NNOX $3.85
- RIGL $38.85
- Analyst Decision
- NNOX Strong Buy
- RIGL Buy
- Analyst Count
- NNOX 2
- RIGL 5
- Target Price
- NNOX $8.50
- RIGL $38.20
- AVG Volume (30 Days)
- NNOX 1.3M
- RIGL 995.6K
- Earning Date
- NNOX 08-12-2025
- RIGL 08-05-2025
- Dividend Yield
- NNOX N/A
- RIGL N/A
- EPS Growth
- NNOX N/A
- RIGL N/A
- EPS
- NNOX N/A
- RIGL 5.43
- Revenue
- NNOX $11,886,000.00
- RIGL $267,921,000.00
- Revenue This Year
- NNOX $24.12
- RIGL $59.93
- Revenue Next Year
- NNOX $160.56
- RIGL N/A
- P/E Ratio
- NNOX N/A
- RIGL $7.15
- Revenue Growth
- NNOX 17.36
- RIGL 105.62
- 52 Week Low
- NNOX $3.75
- RIGL $12.66
- 52 Week High
- NNOX $11.00
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- NNOX 32.78
- RIGL 68.57
- Support Level
- NNOX $3.88
- RIGL $39.00
- Resistance Level
- NNOX $4.16
- RIGL $42.08
- Average True Range (ATR)
- NNOX 0.19
- RIGL 2.32
- MACD
- NNOX -0.02
- RIGL -0.37
- Stochastic Oscillator
- NNOX 8.44
- RIGL 53.26
About NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.